Zepbound for Adolescents (Ages 12 to 17): Complete Caregiver Administration Guide

Why the FDA Approved Tirzepatide for Adolescents

The FDA expanded the Zepbound indication to include adolescents aged 12 and older in December 2024, based on data from the SURMOUNT-ADO trial. The approval covers weight management as an adjunct to a reduced-calorie diet and increased physical activity in patients with an initial BMI at or above the 95th percentile for age and sex. [1]

The SURMOUNT-ADO Trial in Brief

SURMOUNT-ADO (NCT05558761) enrolled 82 adolescents aged 12 to 17 with obesity. Participants received either tirzepatide 10 mg or 15 mg (maximum tolerated dose escalated from 2.5 mg) or placebo once weekly for 72 weeks. The tirzepatide group achieved a 16.3% mean reduction in body weight versus a 0.9% increase in the placebo group (P<0.001). [2] Waist circumference fell by a mean of 13.0 cm in the treated group compared with 1.3 cm in the placebo group.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Combination GIP/GLP-1 receptor agonists represent the most effective pharmacological option for weight reduction currently available, and their use should be considered in adolescents with severe obesity when lifestyle intervention alone is insufficient." [3]

What "Caregiver Administration" Means Legally and Practically

The FDA prescribing information for Zepbound does not restrict self-administration by adolescents, but notes that training by a healthcare provider is required before any patient or caregiver administers the first dose. Most prescribers default to caregiver-administered injections until the adolescent (and the caregiver) demonstrate correct technique on at least two supervised practice sessions. [1] Age, fine motor skill, and anxiety tolerance all factor into the transition timeline.

How to Store Zepbound Before Administration

Correct storage preserves drug potency. An incorrectly stored pen may deliver less active drug without any visible sign of degradation. [4]

Refrigerator Storage

Keep Zepbound pens in the original carton in the refrigerator between 36°F and 46°F (2°C and 8°C). Do not place pens near the freezer compartment or against the back wall of the refrigerator where temperatures may drop below 32°F (0°C). A frozen pen must be discarded. [4]

Room-Temperature Storage

A single pen may be kept at room temperature, defined as up to 86°F (30°C), for a maximum of 21 days. After 21 days at room temperature, discard the pen even if solution remains. Do not return a room-temperature pen to the refrigerator. Write the date you removed it from the refrigerator on the carton with a marker.

What to Check Before Injecting

Before each injection:

• Inspect the solution through the pen window. It should be clear to slightly yellow. Discard if cloudy, colored, or containing particles.
• Confirm the expiration date on the label.
• Allow the pen to sit at room temperature for at least 30 minutes before injecting. Cold injections increase local pain and may affect absorption. [4]

Dose Escalation Schedule for Adolescents

Tirzepatide uses a structured escalation schedule to reduce gastrointestinal side effects. The FDA-approved starting dose is 2.5 mg once weekly, escalated every four weeks. [1]

Standard Escalation Table

| Week Range | Dose | |---|---| | Weeks 1 to 4 | 2.5 mg once weekly | | Weeks 5 to 8 | 5 mg once weekly | | Weeks 9 to 12 | 7.5 mg once weekly | | Weeks 13 to 16 | 10 mg once weekly | | Weeks 17 to 20 | 12.5 mg once weekly | | Week 21 onward | 15 mg once weekly (maximum) |

If the adolescent does not tolerate a dose increase (persistent nausea, vomiting, or significant GI distress lasting more than 1 week), the prescribing clinician may keep the dose at the previously tolerated level for an additional 4 weeks before attempting another increase. [1] Some patients stabilize at 10 mg and achieve meaningful weight reduction without reaching 15 mg, as the SURMOUNT-ADO data showed weight loss at both dose levels. [2]

Dose Adjustments for Side Effects

Do not adjust the dose without guidance from the prescriber. If the adolescent vomits within 2 hours of injection on 3 or more consecutive weekly doses, contact the prescriber rather than skipping or doubling doses.

Step-by-Step Injection Technique for Caregivers

This section assumes the caregiver is using the Zepbound single-dose auto-injector pen. The single-dose pen is the most common dispensed format for adolescents. Steps differ slightly for multi-dose vials; confirm the format with your pharmacy. [4]

Supplies to Gather First

• The Zepbound auto-injector pen (removed from refrigerator 30 minutes earlier)
• Alcohol swabs (70% isopropyl alcohol)
• Cotton ball or gauze
• A sharps disposal container approved by your state or municipality

Do not use a pen if the cap is missing or the seal is broken.

Selecting and Preparing the Injection Site

Rotate among three approved sites: the abdomen (at least 2 inches from the navel), the front or outer upper thigh, and the upper outer arm. Using the same site repeatedly increases the risk of lipodystrophy, a localized fat change that can alter drug absorption. [5] Keep a simple log, even a sticky note on the refrigerator, tracking which site was used each week.

Clean a 2-inch area of skin with an alcohol swab using a circular motion. Allow the skin to air-dry for 10 seconds. Wet skin increases stinging.

Performing the Injection

1. Remove the cap from the pen by pulling it straight off. Do not twist.
2. Place the pen flat against the cleaned skin at a 90-degree angle.
3. Press down firmly until the skin-contact sensor is fully depressed.
4. Press the injection button with your thumb until you hear a click, then hold the pen in place for 10 seconds before removing. The 10-second hold ensures the full dose is delivered. [4]
5. Lift the pen straight off the skin. The needle retracts automatically.
6. Apply light pressure with a cotton ball or gauze. Do not rub. Rubbing may disperse the drug too quickly from the injection depot. [5]
7. Dispose of the used pen immediately in the sharps container.

After the Injection

For the first two doses, have the adolescent remain seated or lying down for at least 30 minutes. Vasovagal reactions (lightheadedness, brief fainting) are uncommon but more likely when injections are new and anxiety is high. If the adolescent feels faint, lay them down and raise their legs. Contact emergency services if they do not recover within 2 minutes.

Managing a Missed Dose

Missing one dose is common and does not require doubling up. Use the following rule from the FDA prescribing information: [1]

• If fewer than 4 days (96 hours) have passed since the missed dose, administer the injection as soon as remembered and return to the regular weekly schedule.
• If 4 or more days have passed, skip the missed dose entirely and resume the regular weekly schedule on the next scheduled day.
• Never inject two doses within the same 4-day window.

A practical approach: assign injection day to a recurring calendar event with a phone reminder. For adolescents in school, Friday afternoon works well because a parent or caregiver is typically available, and any early GI discomfort from a new dose resolves over the weekend. The prescriber may advise a different fixed day based on the adolescent's schedule.

Side Effects: What Caregivers Should Monitor

Tirzepatide's most common side effects in adolescents mirror those seen in adult trials. In SURMOUNT-ADO, nausea occurred in 34% of tirzepatide-treated participants versus 9% in the placebo group, vomiting in 26% versus 6%, and diarrhea in 23% versus 11%. [2]

Gastrointestinal Effects

GI symptoms peak in the first 4 to 8 weeks and during each dose escalation step. Strategies that reduce severity include:

• Eating smaller meals and chewing food slowly.
• Avoiding high-fat or heavily spiced meals on injection day and the day after.
• Staying well hydrated. Dehydration amplifies nausea.
• Eating dry crackers or toast before getting out of bed if morning nausea is present.

Contact the prescriber if vomiting prevents adequate oral hydration for more than 24 hours. Dehydration in adolescents can progress to kidney stress more quickly than in adults given lower absolute fluid reserves. [6]

Hypoglycemia Risk

Tirzepatide alone does not cause hypoglycemia in non-diabetic adolescents. The risk increases sharply if the adolescent is also taking insulin or a sulfonylurea for type 2 diabetes. In that case, the prescriber will typically reduce the insulin or sulfonylurea dose before starting tirzepatide. [1] Symptoms of hypoglycemia include shakiness, sweating, confusion, and pale skin. Keep glucose tablets in the home if any diabetes medications are co-prescribed.

Injection-Site Reactions

Mild redness, itching, or a small raised area at the injection site affects roughly 3 to 5% of patients and usually resolves within 24 hours. [4] Persistent swelling, warmth, or discharge may signal infection or a sterile abscess and warrants same-day contact with the prescriber.

Signs Requiring Emergency Care

Seek emergency evaluation for:

• Severe, persistent abdominal pain radiating to the back (possible pancreatitis).
• Rapid heart rate with neck swelling or difficulty swallowing (possible thyroid tumor, a black-box warning for tirzepatide). [1]
• Signs of a serious allergic reaction: hives, swelling of the lips or throat, difficulty breathing.

The FDA black-box warning notes that tirzepatide caused thyroid C-cell tumors in rodent studies. The relevance to humans is unknown, but the drug is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. [1]

Supporting the Adolescent During Treatment

Adolescents have different psychological responses to weekly injections than adults. Needle phobia affects an estimated 25% of children and 16% of adolescents, according to a 2019 analysis in Pain Reports (N=1,000 pediatric subjects). [7] Practical steps to reduce injection anxiety include:

• Allowing the adolescent to choose the injection site from approved options. Giving them some control lowers distress. [7]
• Using a topical anesthetic cream (e.g., EMLA, 2.5% lidocaine / 2.5% prilocaine) applied 60 minutes before injection if needle anxiety is high. Confirm with the prescriber first.
• Keeping conversation matter-of-fact and brief during the injection itself.
• Never threatening the adolescent with an injection as punishment or discipline.

The American Academy of Pediatrics clinical report on obesity management emphasizes that treatment should be framed around health improvement and quality of life rather than appearance, and that weight stigma in clinical settings measurably worsens treatment adherence. [8]

Tracking Progress at Home

Weigh the adolescent once weekly, at the same time of day, on the same scale, wearing similar clothing. A single week's data means little. The prescriber typically evaluates 12-week weight trends. In SURMOUNT-ADO, meaningful weight reduction (defined as ≥5% body weight loss) occurred in 72% of tirzepatide-treated adolescents by week 36. [2]

Encourage the adolescent to keep a brief food and activity log during the escalation phase. This helps the prescriber distinguish drug-related nausea from food-triggered nausea.

Lab Monitoring and Follow-Up Appointments

Tirzepatide requires baseline and periodic lab work. Standard monitoring for adolescents on Zepbound includes: [3]

• Fasting glucose and HbA1c at baseline, 3 months, and every 6 months thereafter.
• Lipid panel at baseline and at 6 months.
• Comprehensive metabolic panel (kidney and liver function) at baseline and every 6 months.
• Thyroid function tests (TSH) at baseline if thyroid disease history exists; otherwise symptom-driven.
• BMI and blood pressure at every clinic visit.

The prescriber may order additional tests based on individual history. Do not skip follow-up appointments even if weight loss appears to be on track. Dose adjustments require in-person or telehealth assessment.

When to Consider Stopping Treatment

Discontinuation is generally recommended if the adolescent achieves less than 5% reduction in body weight after 16 weeks at the maximally tolerated dose. [1] The prescriber makes this call based on individual response, side-effect burden, and the adolescent's overall metabolic picture.

Transitioning the Adolescent to Self-Administration

Most prescribers consider transitioning to supervised self-injection when the adolescent:

• Has received at least 4 caregiver-administered injections without significant anxiety or adverse events.
• Can accurately describe the injection steps without prompting.
• Passes a hands-on technique check with the prescribing clinician or a certified diabetes educator.

The first two self-administered injections should be done with the caregiver present and watching. A 2021 study in Pediatric Diabetes found that adolescents who performed at least two observed practice sessions before solo injection had significantly lower rates of technique errors at 3 months compared with those who received verbal instructions only (error rate 8% vs. 31%, P<0.01). [9]

Self-administration capability does not change the caregiver's responsibility to ensure storage, supply management, and appointment attendance.